News Reader.info

Results of the STAMPEDE and LATITUDE trials, which investigated the addition of abiraterone and prednisone to androgen-deprivation therapy in advanced prostate cancer, have renewed interest

in 'complete androgen blockade', a concept originally described by Fernand Labrie in the 1980s. However, whether this treatment regimen should become standard of care remains to be

seen. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature

and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues

and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local

taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * James, N. D.

_ et al_. Abiraterone for prostate cancer not previously treated with hormone therapy. _N. Engl. J. Med._ http://dx.doi.org/10.1056/NEJMoa1702900 (2017). * Fizazi, K. _ et al_. Abiraterone

plus prednisone in metastatic, castration-sensitive prostate cancer. _N. Engl. J. Med._ http://dx.doi.org/10.1056/NEJMoa1704174 (2017). * Labrie, F. _ et al_. New approach in the treatment

of prostate cancer: complete instead of partial withdrawal of androgens. _Prostate_ 4, 579–594 (1983). Article  CAS  Google Scholar  * Prostate Cancer Trialists' Collaborative Group.

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. _Lancet_ 355, 1491–1498 (2000). * Akaza, H. _ et al_. Combined androgen blockade with

bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. _Cancer_ 115, 3437–3445 (2009). Article  CAS  Google Scholar  *

Attard, G. _ et al_. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. _J. Clin. Oncol._ 27, 3742–3748 (2009).

Article  CAS  Google Scholar  * Gillessen, S. _ et al_. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference

(APCCC) 2015. _Ann. Oncol._ 26, 1589–1604 (2015). Article  CAS  Google Scholar  * Sweeney, C. J. _ et al_. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. _N. Engl. J.

Med._ 373, 737–746 (2015). Article  CAS  Google Scholar  * James, N. D. _ et al_. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer

(STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. _Lancet_ 387, 1163–1177 (2016). Article  CAS  Google Scholar  * Vale, C. L. _ et

al_. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate

data. _Lancet Oncol._ 17, 243–256 (2016). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Bertrand Tombal is at the Service d'Urologie,

Clinique universitaires Saint Luc, Avenue Hippocrate 10, B-1200 Brussels, Belgium., Bertrand Tombal * Robert J. van Soest is at the Department of Urology, Erasmus University Medical Center,

's-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands., Robert J. van Soest Authors * Bertrand Tombal View author publications You can also search for this author inPubMed Google

Scholar * Robert J. van Soest View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Bertrand Tombal. ETHICS DECLARATIONS

COMPETING INTERESTS B.T. is an investigator and a paid advisor for Astellas, Bayer, Janssen, and Sanofi-Genzyme. R.J.v.S. declares no competing interests. RIGHTS AND PERMISSIONS Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Tombal, B., van Soest, R. STAMPEDE, LATITUDE and Fernand Labrie's legacy. _Nat Rev Urol_ 14, 588–590 (2017).

https://doi.org/10.1038/nrurol.2017.115 Download citation * Published: 18 July 2017 * Issue Date: October 2017 * DOI: https://doi.org/10.1038/nrurol.2017.115 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative